“6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s232. doi:10.25251/skin.7.supp.232.